IBDEI1M2 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27331,1,3,0)
 ;;=3^Electrolyte & Fluid Balance Disorders NEC
 ;;^UTILITY(U,$J,358.3,27331,1,4,0)
 ;;=4^E87.8
 ;;^UTILITY(U,$J,358.3,27331,2)
 ;;=^5003026
 ;;^UTILITY(U,$J,358.3,27332,0)
 ;;=E26.81^^106^1349^5
 ;;^UTILITY(U,$J,358.3,27332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27332,1,3,0)
 ;;=3^Bartter's Syndrome
 ;;^UTILITY(U,$J,358.3,27332,1,4,0)
 ;;=4^E26.81
 ;;^UTILITY(U,$J,358.3,27332,2)
 ;;=^329906
 ;;^UTILITY(U,$J,358.3,27333,0)
 ;;=E23.2^^106^1349^7
 ;;^UTILITY(U,$J,358.3,27333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27333,1,3,0)
 ;;=3^Diabetes Insipidus
 ;;^UTILITY(U,$J,358.3,27333,1,4,0)
 ;;=4^E23.2
 ;;^UTILITY(U,$J,358.3,27333,2)
 ;;=^33572
 ;;^UTILITY(U,$J,358.3,27334,0)
 ;;=E83.41^^106^1349^15
 ;;^UTILITY(U,$J,358.3,27334,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27334,1,3,0)
 ;;=3^Hypermagnesemia
 ;;^UTILITY(U,$J,358.3,27334,1,4,0)
 ;;=4^E83.41
 ;;^UTILITY(U,$J,358.3,27334,2)
 ;;=^5003002
 ;;^UTILITY(U,$J,358.3,27335,0)
 ;;=E21.3^^106^1349^17
 ;;^UTILITY(U,$J,358.3,27335,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27335,1,3,0)
 ;;=3^Hyperparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,27335,1,4,0)
 ;;=4^E21.3
 ;;^UTILITY(U,$J,358.3,27335,2)
 ;;=^331438
 ;;^UTILITY(U,$J,358.3,27336,0)
 ;;=E83.42^^106^1349^21
 ;;^UTILITY(U,$J,358.3,27336,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27336,1,3,0)
 ;;=3^Hypomagnesemia
 ;;^UTILITY(U,$J,358.3,27336,1,4,0)
 ;;=4^E83.42
 ;;^UTILITY(U,$J,358.3,27336,2)
 ;;=^5003003
 ;;^UTILITY(U,$J,358.3,27337,0)
 ;;=N25.1^^106^1349^25
 ;;^UTILITY(U,$J,358.3,27337,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27337,1,3,0)
 ;;=3^Nephrogenic Diabetes Insipidus
 ;;^UTILITY(U,$J,358.3,27337,1,4,0)
 ;;=4^N25.1
 ;;^UTILITY(U,$J,358.3,27337,2)
 ;;=^5015616
 ;;^UTILITY(U,$J,358.3,27338,0)
 ;;=E27.49^^106^1349^2
 ;;^UTILITY(U,$J,358.3,27338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27338,1,3,0)
 ;;=3^Adrenocortical Insufficiency,Other
 ;;^UTILITY(U,$J,358.3,27338,1,4,0)
 ;;=4^E27.49
 ;;^UTILITY(U,$J,358.3,27338,2)
 ;;=^5002743
 ;;^UTILITY(U,$J,358.3,27339,0)
 ;;=E72.09^^106^1349^4
 ;;^UTILITY(U,$J,358.3,27339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27339,1,3,0)
 ;;=3^Amino-Acid Transport Disorders,Other
 ;;^UTILITY(U,$J,358.3,27339,1,4,0)
 ;;=4^E72.09
 ;;^UTILITY(U,$J,358.3,27339,2)
 ;;=^5002895
 ;;^UTILITY(U,$J,358.3,27340,0)
 ;;=N25.89^^106^1349^23
 ;;^UTILITY(U,$J,358.3,27340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27340,1,3,0)
 ;;=3^Impaired Renal Tubular Function Disorders,Other
 ;;^UTILITY(U,$J,358.3,27340,1,4,0)
 ;;=4^N25.89
 ;;^UTILITY(U,$J,358.3,27340,2)
 ;;=^5015618
 ;;^UTILITY(U,$J,358.3,27341,0)
 ;;=E26.89^^106^1349^12
 ;;^UTILITY(U,$J,358.3,27341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27341,1,3,0)
 ;;=3^Hyperaldosteronism,Other
 ;;^UTILITY(U,$J,358.3,27341,1,4,0)
 ;;=4^E26.89
 ;;^UTILITY(U,$J,358.3,27341,2)
 ;;=^5002737
 ;;^UTILITY(U,$J,358.3,27342,0)
 ;;=N25.81^^106^1349^29
 ;;^UTILITY(U,$J,358.3,27342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27342,1,3,0)
 ;;=3^Secondary Hyperparathyroidism of Renal Origin
 ;;^UTILITY(U,$J,358.3,27342,1,4,0)
 ;;=4^N25.81
 ;;^UTILITY(U,$J,358.3,27342,2)
 ;;=^5015617
 ;;^UTILITY(U,$J,358.3,27343,0)
 ;;=E22.2^^106^1349^28
 ;;^UTILITY(U,$J,358.3,27343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27343,1,3,0)
 ;;=3^SIADH
 ;;^UTILITY(U,$J,358.3,27343,1,4,0)
 ;;=4^E22.2
 ;;^UTILITY(U,$J,358.3,27343,2)
 ;;=^5002718
 ;;^UTILITY(U,$J,358.3,27344,0)
 ;;=E87.79^^106^1349^10
 ;;^UTILITY(U,$J,358.3,27344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27344,1,3,0)
 ;;=3^Fluid Overload,Other
